Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Unravelling the role of Pneumocystis jirovecii in utero infection in early and late pulmonary diseases of very preterm infants.

Project description

Predicting pulmonary disease in preterm infants

Pneumocystis jirovecii is a microfungus that causes severe pneumonia in immunosuppressed individuals and may also affect up to 25 % of preterm newborns, increasing the risk of respiratory distress syndrome (RDS) and bronchopulmonary dysplasia. Funded by the Marie Skłodowska-Curie Actions programme, the JIROborn project aims to investigate the impact of P. jirovecii on preterm infants' lungs and subsequent disease development. Researchers will study various clinical parameters, immune responses and microbiota in a large cohort of preterm infants. Alongside genetic information, this data will serve to build a model for predicting an infant’s risk of pulmonary complications.

Objective

Very preterm birth represent about 1% of livebirths in Europe each year and is associated with 58% of neonatal deaths and substantial lifetime health problems. Pneumocystis jirovecii is an ubiquitous microfungus commonly known for causing a severe interstitial
pneumonia in immunosuppressed subjects. However, this could be the tip of the iceberg and compelling new evidences suggest that
this infection may be pathogenic to certain groups of infants.
In utero transmission of P. jirovecii in humans has been recently proven. The fungus has been found in the lungs of 14-25%
preterm newborns, associated with an increased risk of respiratory distress syndrome (RDS) and bronchopulmonary dysplasia. The
ability of P. jirovecii to change the pulmonary environment has been demonstrated in other contexts, inducing a modification of the
host immune response, pulmonary dysbiosis and thickening of pulmonary alveoli. Genetic polymorphisms have also been
independently implicated in both an increased risk of preterm bi or neonatal RDS and a susceptibility to P. jirovecii.
Hence, JIROborn aims to address the impact of P. jirovecii in utero infection on the preterm infants’ lungs alteration and on the
development of subsequent early or late diseases, constructing a predictive model for monitoring preterm infants’ related
pulmonary complications.
JIROborn is a nested case control study using a prospective cohort of 596 infected and uninfected preterm infants and their mothers.
First, the clinical impact of P. jirovecii infection will be evaluated for early and later lung complications. Then, biological effects of the
infection will be studied focusing on the immune parameters, the microbiota and on surfactant and mucus production. Genetic and
epigenetic susceptibilities to P. jirovecii colonization and/or to the development of pulmonary diseases will be evaluated. Finally, all
data will be analysed to build a predictive model for the monitoring of preterm infants’ pulmonary complications.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2023-PF-01

See all projects funded under this call

Coordinator

UNIVERSIDAD DE SEVILLA
Net EU contribution
€ 181 152,96
Address
CALLE S. FERNANDO 4
41004 Sevilla
Spain
Region
Sur Andalucía Sevilla
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data